<DOC>
	<DOCNO>NCT00658606</DOCNO>
	<brief_summary>Assess efficacy safety alefacept nbUVB compare alefacept alone chronic plaque psoriasis subject . Combination therapy may improve clinical response psoriatic subject modality effect T cell</brief_summary>
	<brief_title>Assess Efficacy Safety Alefacept With Narrow Band Ultraviolet B Phototherapy ( nbUVB ) vs. Alefacept Alone Chronic Plaque Psoriasis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Subject give write informed consent Subject diagnosis moderate severe chronic plaque psoriasis involve &gt; =10 % Psoriasis Area Severity Index ( PASI ) score &gt; =10 Baseline Subject CD4+ T lymphocyte ( CD4 ) count lower limit normal Male female subject must use adequate mean contraception screen end study . Subject receive alefacept past Subject show improvement follow adequate course nbUVB past Subject treat past either therapy cyclosporine Subject active cancer , include skin cancer Baseline Subject erythrodermic , pustular predominantly guttate psoriasis Subject use treatment psoriasis prior Baseline follow : Topical treatment within 14 day Oral treatment within 28 day Broad band UVB ( bbUVB ) nbUVB treatment within 56 day Biological treatment within 84 day Serious local infection serious systemic infection within 3 month prior first dose study drug Subject history drug alcohol abuse within past 2 year Subject know infected AIDS virus Subject skin disease disease might interfere psoriasis status assessment Female subject nursing , pregnant planning become pregnant study Subject currently enrol investigational drug device study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>plaque psoriasis</keyword>
	<keyword>alefacept</keyword>
	<keyword>Amevive</keyword>
	<keyword>narrow band ultraviolet B</keyword>
	<keyword>phototherapy</keyword>
</DOC>